Argos Therapeutics Inc fka ARGSQ

[H2R]

Interesting SA interview

http://seekingalpha.com/article/4043028-argos-therapeutics-interview-ceo-jeff-abbey-vp-communications-john-menditto

The summary:

Argos may bring the first precision immunotherapy product to market with Roca-T. Its hard to say, based on the limited patient population their phase 2 trial, whether results will be positive, but based on the more intermediate leaning patient base in phase 3, along with a ~6 month separation goal, management seems to have set the stage for a positive outlook going into mid 2017. There is always the risk that a significant benefit is not shown between control and combo arms, along with the lingering financing needs to maintain cash on hand to get through the year. However, Argos offers an interesting near-term, high-reward opportunity should things go as planned in phase 3.

Good luck to Patients!